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Abstract: Changes in plasma IL-6, plasma VEGF and serum YKL-40 were determined in rheumatoid arthritis (RA) 
patients during treatment with etanercept alone or in combination with methotrexate. Twenty-ﬁ  ve patients with active RA 
(DAS28   3.2) were randomized to receive etanercept (25 mg sc. biweekly) plus methotrexate (n = 12) or etanercept alone 
(n = 13). Plasma IL-6, plasma VEGF and serum YKL-40 were determined by ELISA. The 3 biomarkers and DAS28 scores 
were evaluated at baseline and after 4, 8, 12 and 16 weeks of treatment. At inclusion all patients had signiﬁ  cantly (p   0.001) 
elevated plasma IL-6, plasma VEGF and serum YKL-40 compared to healthy subjects. Eighteen patients responded to 
treatment (pooled data from both treatment groups), and they had signiﬁ  cant (p   0.05 to p   0.001) decreases in plasma 
IL-6, plasma VEGF, serum YKL-40, ESR and DAS28 after 4 weeks of treatment and throughout the study (except serum 
YKL-40 at week 16). Plasma IL-6 showed the largest reductions. Non-responders had unchanged biomarkers. At week 16 
the patients with DAS28   3.2 had lower levels compared to baseline values in plasma IL-6 (p = 0.005), plasma VEGF 
(p = 0.014), and ESR (p = 0.024).
Plasma IL-6, plasma VEGF and serum YKL-40, which reﬂ  ect different aspects of the inﬂ  ammatory process, may provide 
useful information regarding early differentiation of responders from non-responders.
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Introduction
Etanercept, a tumor necrosis factor-alpha (TNF-α) receptor antagonist, in combination with methotrexate 
has shown to be more effective than etanercept or methotrexate alone for control of disease activity 
in patients with rheumatoid arthritis (RA).
1 With the development of new targeted therapies for RA 
there is a need for more sensitive and specific assessment of treatment response. Molecular 
markers produced locally in the arthritic joint may reﬂ  ect the inﬂ  ammatory and destructive processes 
in RA, and quantiﬁ  cation of these may be a useful adjunct to the clinical evaluation of these 
patients.
Interleukin-6, produced in the arthritic joint by T and B lymphocytes, macrophages, synoviocytes, 
osteoblasts and mast- and endothelial cells, plays important roles in the inﬂ  ammatory processes 
seen in RA.
2 The sources of VEGF in RA patients are the synovial lining cells, macrophages, leu-
kocytes, platelets, ﬁ  broblasts and endothelial cells.
3 VEGF stimulates angiogenesis (i.e. the forma-
tion of new vessels from pre-existing ones),
4 which constitute an early event in RA and may lead 
to cartilage and bone destruction in later stages of the disease.
4 YKL-40 (chitinase-3-like 1 protein) 
is produced locally in the arthritic joint by activated macrophages, chondrocytes, synoviocytes and 
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neutrophils.
2,5,6 YKL-40 is found to be a possible 
auto antigen in RA.
7
We studied the short time changes in plasma 
IL-6, plasma VEGF and serum YKL-40 in RA 
patients receiving either etanercept alone or in 
combination with MTX.
Materials and Methods
Patients and therapy
Twenty-f  ive Danish RA patients, who accepted 
participation in a prospective, randomized, interna-
tional study (Protocol Number 0881A1-101136, 
The ADORE study),
8 were enrolled in this 
investigator-initiated amendment involving repeated 
measurements of plasma IL-6, plasma VEGF and 
serum YKL-40. All patients received methotrexate 
(for minimum 3 months prior to the study and a 
stable dose for 6 weeks prior to inclusion), but their 
disease activity was inadequately controlled (i.e. 
disease activity score (based on 28 joint counts 
and the erythrocyte sedimentation rate (ESR), 
DAS28   3.2).
9 The patients were randomized to 
receive either etanercept plus methotrexate (n = 12, 
group A) or etanercept alone (n = 13, group B). 
Group B patient’s tapered methotrexate during a 
period of 4 weeks. No patients received intra-
articular or systemic steroid injections within 
4 weeks before screening. Five patients received a 
stable dose of oral corticosteroid 4 weeks prior to 
and throughout the study. Clinical evaluation 
and blood samples were collected at baseline and 
after 4, 8, 12 and 16 weeks of treatment.
The study was performed in accordance with 
the Helsinki Declaration II and approved by the 
local ethical committee.
Biochemical analysis
Blood samples were centrifuged within 3 hours after 
venipuncture and stored at −80 
οC until analysis. 
ESR was determined by routine method. The 
biomarkers were determined by ELISA: plasma 
IL-6 and plasma VEGF (R&D Systems, Oxon, 
U.K), and serum YKL-40 (Quidel, CA, U.S.A.). 
Samples from each patient were analyzed on the 
same ELISA plate with internal control samples on 
each plate to conﬁ  rm assay precision.
Healthy subject population
The plasma IL-6 concentration in 318 healthy 
subjects (median age 48 years, range 18–64, 122 
women and 196 men) was median 1.3 ng/l (90th 
percentile = 3.3 ng/l). The plasma VEGF level in 
306 healthy subjects (median age 48 years, range 
18–64, 116 women and 190 men) was median 
45 ng/l (90th percentile = 109 ng/l). The serum 
YKL-40 in 245 healthy subjects (median age 
49 years, range 18–79, 134 women and 111 men) 
was median 43 μg/l (90th percentile = 95 μg/l).
Statistical analysis
Results are given as median, range and percentage 
changes from baseline. Comparison between and 
within groups was done by Mann-Whitney and 
Wilcoxon-Pratt tests, respectively. Correlation was 
calculated by Spearman’s test. P   0.05 were 
considered statistically signiﬁ  cant. The statistical 
tests used are all non-parametric since the inter-
leukin-6, vascular endothelial growth factor and 
YKL-40 are not normally distributed according to 
a normal probability plot. Areas under the curve 
(AUC) values, i.e. weighted means, were calcu-
lated for each parameter. The patients were divided 
according to the EULAR response criteria, into 
clinical responders (EULAR good or moderate 
responders) and clinical nonresponders (EULAR 
non-responders) (www.das-score.nl). For statistical 
calculations, Sigma Stat (SPSS Inc., Chicago, IL, 
USA, version 3.1) was used.
Results
Clinical and biochemical parameters at baseline 
are given in Table 1. The patients had increased 
plasma IL-6 (p   0.001), plasma VEGF (p   0.008) 
and serum YKL-40 (p   0.001) compared to 
healthy subjects. There were no signiﬁ  cant differ-
ences in the biomarkers between the two treatment 
groups at baseline or throughout the study. Accord-
ing to the EULAR response criteria (www.das-
score.nl), 18 patients (group A: n = 10, group B: 
n = 8) had good (n = 8) or moderate response 
(n = 10) at the end of the study. Five patients were 
non-responders (group B) and 2 withdrew due to 
adverse events (group A). At baseline DAS28 
correlated with ESR (rho = 0.52, p = 0.008) and 
serum YKL-40 (rho = 0.44, p = 0.03), plasma IL-6 
with ESR (rho = 0.56, p = 0.003), and HAQ with 
serum YKL-40 rho = 0.52, p = 0.01), ESR 
(rho = 0.50, p = 0.01) and DAS28 (rho = 0.72, 
p   0.0001).
Figure 1 illustrates the individual changes in 
clinical and biochemical markers in the RA patients 93
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according to the EULAR DAS28 response criteria. 
Table 2 shows the percentage decreases compared 
to baseline values. Signif  icant decreases from 
baseline values were found in plasma IL-6, plasma 
VEGF, ESR, and DAS28 at 4, 8, 12 and 16 weeks 
and in serum YKL-40 at 4, 8 and 12 weeks 
(p = 0.03 to p   0.001). Plasma IL-6 and DAS28 
showed the most pronounced reductions. All bio-
markers, HAQ and DAS28 decreased in both 
treatment arms, and there was no signiﬁ  cantly dif-
ferences between group A and B. No signiﬁ  cant 
changes were found in the biomarkers of the non-
responders. The only AUC value that correlated 
was plasma IL6AUC versus ESRAUC (rho = 0.79, 
p = 0.004).
At week 16, eleven patients had low disease 
activity (DAS28   3.2), and 7 of whose were in 
remission (DAS28   2.6). Patients with 
DAS28   3.2 at week 16 had lower plasma IL-6 
levels at this time point compared to baseline level 
(4.1 vs. 9.6 ng/l, p = 0.005), ESR (8 vs. 16 mm/h, 
p = 0.024) and plasma VEGF (74 vs. 126 ng/l, 
p = 0.014). No signiﬁ  cant change was found in 
serum YKL-40. At week 16 plasma IL-6 was 
signiﬁ  cantly higher in RA patients who were in 
remission compared to healthy subjects (4.1 vs. 
1.3 ng/l, p   0.005) whereas plasma VEGF (81 vs. 
45 ng/l, p = 0.318) and serum YKL40 were not (66 
vs. 43 μg/l, p = 0.063).
Discussion
In this study we focused on changes in circulating 
levels of IL-6, VEGF and YKL-40 in RA patients 
during anti-TNF-α therapy. TNF-α, IL-1, and 
IL-17 augment the production of IL-6 by synovial 
cells and IL-6 is found to be responsible for many 
of the clinical and biochemical changes in RA.
2 
TNF-α and several pro-inﬂ  ammatory cytokines 
(i.e. IL-1, IL-6, IL-8) induce VEGF production 
and these cytokines are responsible for over-
expression of VEGF seen in RA.
3 IL-1 and TNF-α 
induces YKL-40 expression and synthesis by 
chondrocytes and requires activation of nuclear 
factor kappa B.
10 In accordance with others
11–13 
we found that plasma IL-6, plasma VEGF and 
serum YKL-40 were signif icantly increased in RA 
patients compared to healthy subjects, and that 
these markers decreased during anti-TNF-α 
therapy.
5,6,14 Etanercept, a construct comprising 
two human p75 TNF-α receptors coupled to the 
Fc portion of a monoclonal human antibody 
(IgG1), binds both TNF-α and TNF-β and thereby 
reducing cytokine production in patients with 
RA.
15 Methotrexate is known to reduce cytokine 
production through apoptosis of peripherally active 
T-cells and reduce the number of macrophages in 
the synovial tissue.
16 Even though etanercept was 
able to decrease plasma IL-6, plasma VEGF and 
serum YKL-40, the level of plasma IL-6 was 
Table 1. Clinical and biochemical parameters before treatment with etanercept.
Parameters Median (min–max) Elevated level ¤
Sex, n (female/male) 17/8
Age (years) 61 (38–82)
Disease duration (years) 12.5 (1–48)
Methotrexate dose (mg, weekly) 15 (12.5–25)
Swollen joint count (range 0–28) 14 (3–24)
Tender joint count (range 0–28) 16.5 (2–28)
HAQ (range 0–3) 1.75 (0–2.875)
DAS28 (ESR) 5.8 (3.1–7.4)
Rheumatoid factor (kiu/l, normal level   17) 72.5 (10–971) 23/25 (92%)
ESR (mm/h, normal level   20)
§ 23 (3–96) 13/23 (52%)
Plasma IL-6 (ng/l, normal level   3.3) 10 (1.8–68) 20/25 (80%)
Plasma VEGF (ng/l, normal level   109) 92 (7–320) 10/25 (40%)
Serum YKL-40 (μg/l, normal level   95) 108 (25–777) 17/25 (68%)
§ESR at baseline is missing in 2 patients. 
¤The proportion of patients with elevated baseline level of the parameter.
Abbreviations: HAQ, Health Assessment Questionnaire; DAS28, Disease Activity Score; ESR, Erythrocyte Sedimentation Rate; IL-6, 
Interleukin-6; VEGF, Vascular Endothelial Growth Factor; YKL-40, Human cartilage glycoprotein 39, CHI3L1.94
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Figure 1. The changes in plasma IL-6, plasma VEGF, serum YKL-40, ESR and DAS28(ESR) in 25 RA patients during the 16-week study 
period, divided by being EULAR good/moderate responders or EULAR non-responders. Values are given as box and whiskers plots. Boxes 
indicate 25th, 50th, 75th centiles. Whiskers indicate 5th–95th percentiles. The y-axis is logarithmic for the biomarkers. *, ** and *** indicate 
statistically signiﬁ  cant changes from baseline (Wilcoxon-Pratt): *p   0.05, **p   0.01, ***p   0.001.
signif  icantly higher in RA patients in remission 
than in healthy subject, whereas VEGF and 
YKL-40 were not. The disease process in the joints 
not being fully suppressed, despite the low clinical 
disease activity could explain this. As suggested 
by others non-responsiveness to TNF-α blockade 
and residual disease activity, indicate that TNF is 
not the sole responsible biological target in RA.
17 
Prospective studies including a larger number of 
RA patients are needed to evaluate if these bio-
markers, can provide useful information regarding 
early differentiation of responders from non-
responders.
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Table 2. Relative decrease in clinical and biochemical parameters compared to baseline values.
4 weeks 8 weeks 12 weeks 16 weeks
Responders (n = 18)
Plasma IL-6 30* (15) 42*** (11) 47*** (13) 28*** (28)
Plasma VEGF 13** (25) 43*** (5) 19* (13) 4* (17)
Serum YKL-40 28*** (7) 33*** (5) 20* (8) 17 (13)
ESR 44*** (4) 35*** (8) 42** (10) 44** (10)
DAS28 33*** (4) 38*** (5) 38*** (5) 43*** (4)
HAQ 48*** (7)
Non-Responders (n = 5)
Plasma IL-6 32
NS (18) −39
NS (40) 38
NS (3) −34
NS (66)
Plasma VEGF −65
NS (64) −49
NS (14) −10
NS (36) 16
NS (44)
Serum YKL-40 20
NS (10) −17
NS (9) −28
NS (9) −16
NS (6)
ESR −10
NS (19) −4
NS (37) −5
NS (46) −33
NS (68)
DAS28 20
NS (9) 10
NS (6) 7
NS (13) 14
NS (1)
HAQª 100
NS (100)
The relative decreases, expressed in%, compared to baseline values are given as mean values (standard error of mean). Negative values 
indicate an increase compared to baseline level. *p   0.05, **p   0.01, and ***p   0.001.
Abbreviations: HAQ, Health Assessment Questionnaire; DAS28, Disease Activity Score; ESR, Erythrocyte Sedimentation Rate; IL-6, 
Interleukin-6; VEGF, Vascular Endothelial Growth Factor; YKL-40, Human cartilage glycoprotein 39, CHI3L1.